About 32 results found for searched term "SMA4" (0.099 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M17472 | Eudesmane-1β,4β,7α-triol | Sesquiterpenoids |
| Eudesmane-1β,4β,7α-triol | ||
| M43069 | SMA4 | Others |
| SMA4 is a selective PKG1α activator with basal EC50 value of 29 μM. | ||
| M1647 | AMG-208 | c-Met |
| AMG208 | ||
| AMG-208 is a potent small molecular inhibitor c-Met with an IC50 of 9.3 nM. AMG-208 is also a CYP3A4 inhibitor with an IC50 of 32 μM. AMG-208 has anti-cancer activity. | ||
| M1682 | BMS-777607 | c-Met |
| BMS 817378; CAS# 1025720-94-8 | ||
| BMS-777607 is a selective and potent small-molecule met kinase inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. | ||
| M1694 | CYC116 | Aurora Kinase |
| CYC116 is a potent, small molecule inhibitor of Aurora A, B and C with IC50 value of 44, 19 and 65 nM respectively. CYC-116 also inhibits VEGFR2, Src, Lck AND FLT3 with with Kis of 44, 82, 280, 44 nM, respectively. CYC-116 may have broad-spectrum antitumor activity. | ||
| M1749 | Gefitinib | EGFR/HER2 |
| ZD-1839, Iressa | ||
| Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. | ||
| M1751 | MLN8054 | Aurora Kinase |
| MLN8054 is an orally bioavailable, highly selective small molecule inhibitor of Aurora with IC50s of 0.004uM and 0.172uM. for Aurora A and Aurora B. | ||
| M1765 | Crizotinib (PF-02341066) | c-Met |
| Crizotinib | ||
| Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively. | ||
| M1766 | PF-04217903 | c-Met |
| PF-4217903 | ||
| PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to142 nM. | ||
| M1771 | Ataluren | CFTR |
| PTC124 | ||
| Ataluren (PTC124) is a novel, orally available small molecular CFTR-G542X nonsense allele inhibitor. | ||
| M1786 | Ispinesib | Kinesin |
| SB-715992, CK0238273 | ||
| Ispinesib (SB 715992) is the first potent, highly specific small-molecule inhibitor of kinesin spindle protein (KSP) with an IC50 of 4.1 nM. | ||
| M1793 | JNJ-38877605 | c-Met |
| JNJ38877605 | ||
| JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met with an IC50 of 4 nM. | ||
| M1796 | XAV939 | Wnt/beta-catenin |
| NVP-XAV939; XAV-939 | ||
| XAV939 is a potent, cell-permeable small molecule inhibitor of the Wnt/β-catenin pathway to TNKS1 and TNKS2 with IC50 values of 11 and 4 nM respectively. | ||
| M1824 | SRT1720 Hydrochloride | Sirtuin |
| SRT-1720 Hydrochloride | ||
| SRT1720 Hydrochloride is a selective small molecule activator of SIRT1 that is 1,000-fold more potent than resveratrol (EC1.5 = 0.16 versus 46.2 µM, respectively). SRT1720 increased the activity of SIRT1 and AMPKα phosphorylation at Ser485 via the cAMP-protein kinase A (PKA) pathway. | ||
| M1869 | Dacomitinib | EGFR/HER2 |
| PF-00299804 | ||
| Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. | ||
| M1899 | PHA-665752 | c-Met |
| PHA-665752 is a selective small molecule c-MET inhibitor (Ki of 4 nM, IC50 of 9 nM). | ||
| M1956 | Apatinib mesylate | VEGFR/PDGFR |
| Rivoceranib mesylate; YN968D1 | ||
| Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor of VEGFR2 with an IC50 of 2.43 nM. | ||
| M1994 | Telatinib | VEGFR/PDGFR |
| BAY 57-9352 | ||
| Telatinib (BAY 57-9352) is an orally active small-molecule tyrosine kinase inhibitor of VEGFR2, VEGFR3 and PDGFRβ with IC50 of 6 nM, 4 nM and 15 nM, respectively. | ||
| M2023 | Bemcentinib | TAM Receptor |
| R428; BGB324 | ||
| Bemcentinib (R428) is a potent and selective small-molecule inhibitor of Axl kinase with IC50 of 14 nM. | ||
| M2030 | Apremilast | PDE |
| CC-10004 | ||
| Apremilast is a novel, orally available small molecule inhibitor of PDE4 with IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM. | ||
| M2035 | IU1 | Proteasome |
| IU1 is a reversible, small molecule inhibitor of deubiquitination by USP14 that demonstrates an IC50 value of 4-5 μM. | ||
| M2070 | XL888 | HSP |
| XL888 is a novel small-molecule inhibitor of HSP90 with IC50 of 24 nM. | ||
| M2111 | Fimepinostat | HDAC |
| CUDC-907 | ||
| Fimepinostat (CUDC-907) is a potent, orally-available small molecule dual PI3K and HDAC inhibitor, with IC50 values of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10, respectively. | ||
| M2148 | RKI-1447 | ROCK |
| RKI-1447 is a potent small molecule inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 6 nM, respectively. | ||
| M2166 | Birinapant | IAP |
| TL32711 | ||
| Birinapant (TL32711) is a bivalent Smac analogue, which is a potent antagonist of XIAP and cIAP1 with Kd values of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces autoubiquitination and proteasome degradation of cIAP1 and cIAP2 in intact cells, resulting in the formation of RIPK1: Caspase-8 complex, which activates and induces tumor cell death. | ||
| M2189 | Pevonedistat | NEDD8-activating Enzyme |
| MLN4924; MLN-4924 | ||
| Pevonedistat (MLN4924) is a first-of-its-kind (first-in-class) small molecule inhibitor of Nedd8 activating enzyme (NAE) with an IC50 of 4.7 nM. | ||
| M2598 | Inauhzin | p53 |
| INZ | ||
| Inauhzin is a novel small molecule that effectively reactivates p53 by inhibiting SIRT1 activity, promotes p53-dependent apoptosis of human cancer cells without causing apparently genotoxic stress(IC50=3 uM, in A549 cell). | ||
| M2334 | EPZ004777 | Histone Methyltransferase |
| EPZ004777 is a potent, selective, small-molecule inhibitor of DOT1L with IC50 of 0.4 nM. | ||
| M2463 | BMS-663068 | HIV Protease |
| Fostemsavir | ||
| BMS-663068 is a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells with EC50 of < 10 nM. | ||
| M2608 | Kobe0065 | Ras |
| Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD, exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM. | ||
| M2700 | FH1 | Others |
| NSC 12407; BRD-K4477 | ||
| FH1 (BRD-K4477) is a small molecule, which promotes differentiation of iPS-derived hepatocytes. FH1 (NSC 12407) enhances hepatocyte functions, and promotes the differentiation of induced pluripotent stem (iPS)-derived hepatocytes toward a phenotype more mature and the maturation of well-differentiated cultures of hepatocyte-like cells (iHeps). | ||
| M2800 | KY02111 | Others |
| KY02111 is a widely used small molecule that boosts cardiomyogenesis. Chemical genetics of KY02111 identified squalene synthase (SQS) as a molecular target of KY02111. By disrupting the interaction of SQS with cardiac ER-membrane protein TMEM43, KY02111 impairs TGFβ/SMAD signaling and recapitulates the clinical mutation of TMEM43 that causes an inherited heart disease. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
